Tags

Type your tag names separated by a space and hit enter

Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors.
Clin Immunol. 2022 Nov; 244:109103.CI

Abstract

The severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) survivors are more likely to produce a potent immune response to SARS-CoV-2 after booster vaccination. We assessed humoral and T cell responses against SARS-CoV-2 in previously vaccinated SARS-CoV-1 survivors and naïve healthy individuals (NHIs) after a booster Ad5-nCoV dose. Boosted SARS-CoV-1 survivors had a high neutralization of SARS-CoV-2 Wuhan-Hu-1 (WA1), Beta, and Delta but is limited to Omicron subvariants (BA.1, BA.2, BA.2.12.1, and BA.4/BA.5). Most boosted SARS-CoV-1 survivors had robust SARS-CoV-2-specific CD4+ and CD8+ T cell responses. While booster vaccination in NHIs elicited less or ineffective neutralization of WA1, Beta, and Delta, and none of them induced neutralizing antibodies against Omicron subvariants. However, they developed comparable SARS-CoV-2-specific T cell responses compared to boosted SARS-CoV-1 survivors. These findings suggest that boosted Ad5-nCoV would not elicit effective neutralizing antibodies against Omicron subvariants in SARS-CoV-1 survivors and NHIs but induced comparable robust T cell responses. Achieving a high antibody titer in SARS-CoV-1 survivors and NHIs is desirable to generate broad neutralization.

Links

Authors+Show Affiliations

School of Pharmacy, Minzu University of China, Beijing, China; Key Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, Beijing, China.

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China; Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.

School of Pharmacy, Minzu University of China, Beijing, China; Key Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, Beijing, China.

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China; Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China. Electronic address: mjma@163.com.

MeSH

AIDS VaccinesAntibodies, NeutralizingAntibodies, ViralBCG VaccineCOVID-19COVID-19 VaccinesDiphtheria-Tetanus-Pertussis VaccineHumansInfluenza VaccinesMeasles-Mumps-Rubella VaccinePapillomavirus VaccinesRespiratory Syncytial Virus VaccinesSAIDS VaccinesSARS-CoV-2Survivors

Pub Type(s)

Journal Article

Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

36049602

Citation

Lu, Bi-Nan, et al. "Antibody and T-cellular Response to COVID-19 Booster Vaccine in SARS-CoV-1 Survivors." Clinical Immunology (Orlando, Fla.), vol. 244, 2022, p. 109103.

Lu BN, Zhu KL, Cui XM, et al. Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors. Clin Immunol. 2022;244:109103.

Lu, B. N., Zhu, K. L., Cui, X. M., Yao, L., Wang, X. J., Wang, G. L., Duan, L. J., Qian, A., & Ma, M. J. (2022). Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors. Clinical Immunology (Orlando, Fla.), 244, 109103. https://doi.org/10.1016/j.clim.2022.109103

Lu BN, et al. Antibody and T-cellular Response to COVID-19 Booster Vaccine in SARS-CoV-1 Survivors. Clin Immunol. 2022;244:109103. PubMed PMID: 36049602.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors. AU - Lu,Bi-Nan, AU - Zhu,Ka-Li, AU - Cui,Xiao-Ming, AU - Yao,Lin, AU - Wang,Xue-Jun, AU - Wang,Guo-Lin, AU - Duan,Li-Jun, AU - Qian,Aruna, AU - Ma,Mai-Juan, Y1 - 2022/08/29/ PY - 2022/08/04/received PY - 2022/08/22/accepted PY - 2022/9/2/pubmed PY - 2022/10/13/medline PY - 2022/9/1/entrez KW - Booster vaccination KW - Omicron KW - SARS-CoV-1 survivors KW - SARS-CoV-2 KW - T-cell response SP - 109103 EP - 109103 JF - Clinical immunology (Orlando, Fla.) JO - Clin Immunol VL - 244 N2 - The severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) survivors are more likely to produce a potent immune response to SARS-CoV-2 after booster vaccination. We assessed humoral and T cell responses against SARS-CoV-2 in previously vaccinated SARS-CoV-1 survivors and naïve healthy individuals (NHIs) after a booster Ad5-nCoV dose. Boosted SARS-CoV-1 survivors had a high neutralization of SARS-CoV-2 Wuhan-Hu-1 (WA1), Beta, and Delta but is limited to Omicron subvariants (BA.1, BA.2, BA.2.12.1, and BA.4/BA.5). Most boosted SARS-CoV-1 survivors had robust SARS-CoV-2-specific CD4+ and CD8+ T cell responses. While booster vaccination in NHIs elicited less or ineffective neutralization of WA1, Beta, and Delta, and none of them induced neutralizing antibodies against Omicron subvariants. However, they developed comparable SARS-CoV-2-specific T cell responses compared to boosted SARS-CoV-1 survivors. These findings suggest that boosted Ad5-nCoV would not elicit effective neutralizing antibodies against Omicron subvariants in SARS-CoV-1 survivors and NHIs but induced comparable robust T cell responses. Achieving a high antibody titer in SARS-CoV-1 survivors and NHIs is desirable to generate broad neutralization. SN - 1521-7035 UR - https://www.unboundmedicine.com/medline/citation/36049602/Antibody_and_T_cellular_response_to_COVID_19_booster_vaccine_in_SARS_CoV_1_survivors_ DB - PRIME DP - Unbound Medicine ER -